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Background:  Protection  of  newborns  and  young  infants  against  RSV  disease  via  maternal  immunization
mediated  by  transplacental  transfer  of antibodies  is under  evaluation  in  third-trimester  pregnant  women
with  the RSV  recombinant  F  nanoparticle  vaccine  (RSV  F vaccine).  Since  the  hemichorial  placental  archi-
tecture in guinea  pigs  and  humans  is  similar,  the  guinea  pig  model  was  employed  to assess  RSV  F  vaccine
immunogenicity  in pregnant  sows  and  to  compare  RSV-speciﬁc  maternal  antibody  levels  in  their  pups.
Methods:  Thirty  (30)  presumptive  pregnant  guinea  pigs  were immunized  on  gestational  day  25 and  46
with placebo  (PBS),  30 g RSV  F,  or 30  g RSV  F +  400  g aluminum  phosphate.  Sera  at delivery/birth
(sows/pups)  and  15  and  30 days  post-partum  (pups)  were  analyzed  for the  presence  of anti-F  IgG,
palivizumab-competitive  antibody  (PCA)  and  RSV/A  microneutralization  (MN).
Results:  The  rates  of  pregnancy  and  stillbirth  were  similar  between  controls  and vaccinees.  The  vaccine
induced  high  levels  of anti-F  IgG,  PCA  and MN in  sows,  with  the  highest  levels  observed  in adjuvanted
vaccinees.  Placental  transfer  to pups  was  proportional  to the  maternal  antibody  levels,  with  concentration
effects  observed  for all  immune  measures.
Conclusions:  The  RSV  F vaccine  was  safe  and  immunogenic  in  pregnant  guinea  pigs  and supported  robust
transplacental  antibody  transfer  to their  pups. Relative  concentration  of antibodies  in the  pups  was
observed  even  in  the  presence  of  high  levels  of  maternal  antibody.  Guinea  pigs  may  be an  important  safety
and  immunogenicity  model  for  preclinical  assessment  of  candidate  vaccines  for  maternal  immunization.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Protection of newborns and young infants against infectious
isease via maternal immunization is an increasingly utilized
ntervention with strikingly effective outcomes [1–3]. Maternal
mmunization is an important strategy to protect infants against
SV where the peak hospitalization rates occur in the youngest
nfants [4]. In mammals, the passage of maternal antibodies to
aïve offspring is largely achieved by either in utero transpla-
ental transfer of IgG or post-partum breast-feeding of colostral
ilk containing high levels of IgG and sIgA [5]. In ungulates, the
ransfer of antibodies from mother to infant occurs exclusively
hrough colostral milk given at the ﬁrst feeding [5]. In these ani-
als the intestinal uptake of maternally derived colostral antibody
ia intestinal Fc receptors results in high serum levels of antibodies
6]. Poor outcomes due to common pathogens in otherwise healthy
∗ Corresponding author. Tel.: +1 240 268 2000; fax: +1 240 268 2100.
E-mail address: gglenn@novavax.com (G.M. Glenn).
ttp://dx.doi.org/10.1016/j.vaccine.2015.08.039
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
newborn animals are frequently observed when colostral feeding
does not occur (e.g., maternal demise during delivery).
For human infants, maternal-derived IgG appears to be pro-
vided entirely in utero, via transplacental Fc receptor-mediated
antibody transfer [5]. Although humans seem to lack, or at least
have inefﬁcient colostral/intestinal IgG antibody uptake, there
is important and well-described documentation of neonatal Fc
receptor-mediated transport of IgG across the epithelial barrier; i.e.,
from the systemic circulation to the mucosal surface and sampling
of antigen-antibody complexes in the intestine by local immune
cells [7]. While it is clear that human breast milk contains both poly-
clonal IgG and IgA and confers protection against respiratory and
enteric illness in general [8]. The precise mechanism underlying
this protection is unclear, but may  be due to direct contact between
antibodies in milk and pathogens in the upper respiratory tract and
gut. Conversely, the protective effects of human serum IgG, trans-
ferred from mothers to infants in utero [5], has been well-described
against many infectious disease agents [2,9,10].
As the acceptance of maternal immunization via transplacen-
tal transfer grows as a viable strategy for protection of newborns
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
G.M. Glenn et al. / Vaccine 33 (2015) 6488–6492 6489
Table  1
Study design.
Blood collection
Treatment group Pregnant guinea pigs (N) Antigen Immunization (gestation day) Sows Pups
1 10 Placebo (PBS) GD25, GD46 PND0 PND0, PND15, PND30
2  10 30 g RSV F
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D: Gestation Day; PND: Post Natal Day; AlPO4 = Aluminum Phosphate.
gainst disease early in life, so does the urgency to develop robust
afety and immunogenicity datasets in a relevant preclinical model.
he placental structure supports the physiologic transfer of nutri-
nts, oxygen and antibodies to the fetus—a function achieved
ithout admixing of maternal and fetal blood [5]. The hemichorial
lacental architecture in guinea pigs reﬂects the anatomy found
n humans and thus represents a potentially appropriate model
o evaluate placental transfer of antibodies. An experimental RSV
ecombinant F nanoparticle vaccine (RSV F vaccine) has progressed
o evaluation in third-trimester pregnant women (Clintrials.gov,
CT02247726), with earlier studies in women of childbearing age
aving shown the vaccine induces F protein speciﬁc antibodies as
easured by several clinically relevant assays (i.e., anti-F IgG and
alivizumab-competitive antibody (PCA) ELISA, and microneutral-
zation [6]). In support of this work, the guinea pig model was
mployed to further assess the immunogenicity of this experi-
ental vaccine in pregnant sows and to compare antibody levels
lacentally-transferred to their pups using the same immunologi-
al measures aforementioned. Although the guinea pig model is an
mmune naïve model and may  differ in some respects compared to
dult women who are primed with years of repeat RSV infections,
he results of this study represent a key dataset toward building
 risk-beneﬁt proﬁle for use of the RSV F nanoparticle vaccine in
regnant women.
. Material and methods
.1. Vaccine
The RSV F vaccine was manufactured by infecting Spodoptera
rugiperda cells in exponential growth with baculovirus containing
he near full-length RSV F gene sequence, as previously described
11]. The F protein, which forms nanoparticles of approximately
0 nm in diameter, was further formulated in buffer containing
5 mM sodium phosphate, pH 6.2, 1% histidine, 0.01% PS80 and
hen adsorbed to aluminum phosphate (AlPO4, Brenntag Biosector,
rederikssund, Denmark).
.2. Animals
The in-life portion of the study was performed under Good Labo-
atory Practice (GLP) regulations at Smithers Avanza (Gaithersburg,
D)  to generate controlled pregnancy and pup delivery data. Thirty
30) presumed pregnant female Hartley guinea pigs were obtained
rom Charles River Laboratories, Canada, on the 20th day of ges-
ation (GD20). To improve the rate of pregnancy, guinea pigs with
rior history of more than one successful pregnancy were selected
or the current study. In addition, females were not palpated or bled
uring the gestation period to avoid stress to the pregnant sows and
etuses. Guinea pigs were weighed upon arrival and randomized
wo days later based on similar body weight distribution into 1 of treatment groups with 10 animals each. All serologies were per-
ormed via orbital sinus or cardiac puncture following isoﬂurane
nhalation or intraperitoneal injection of Euthansol, an euthanasia
olution.2.3. Guinea pig immunization
Presumed pregnant guinea pigs were immunized as described
in Table 1. Pregnant females in Group 1 (placebo) received an intra-
muscular (IM) administration of PBS in a volume of 250 L per
guinea pig on GD25 and 46. Animals in Group 2 (30 g RSV F)
and Group 3 (30 g RSV F + 400 g AlPO4) received an IM admin-
istration of antigen alone or with adjuvant in a volume of 250 L
per guinea pig on GD25 and GD46 also. Guinea pigs (sows) were
bled on Post Natal Day (PND) 0 (i.e., at delivery). Pups assigned to
the PND0 (n = 14–17) phlebotomy cohort were terminally bled on
delivery day. The remaining pups (n = 14–17) that were left with
birth mothers until weaning (i.e., on PND15), were bled on PND15
and PND30.
2.4. Anti-RSV F IgG ELISA and palivizumab-competitive antibody
ELISA
Anti-RSV antibody levels based on anti-RSV F IgG and
palivizumab-competitive binding with biotin-labeled palivizumab
(MedImmune, LLC) were assessed at Novavax as previously
described [11] on sera obtained from pregnant guinea pigs on
PND0 and from their pups on PND0, PND15, and PND30. For anti-
F IgG, data was analyzed using SoftMax pro software (Molecular
Devices) using a 4-parameter logistics (4-PL) curve ﬁt analysis.
Titers were reported as the reciprocal dilution that resulted in a
reading of 50% the maximum OD. Titer values recorded as below
the lower limit of detection (LLOD) were assigned a titer of <100
for the sample, and a titer of 50 for the geometric mean titer (GMT)
analysis.
Antibodies competitive with palivizumab were quantitated
using a 4-PL curve ﬁt curve analysis, and the serum dilution that
resulted in 50% inhibition of palivizumab binding was  calculated
as follows:(
ODpalivizumab − ODsample
ODpalivizumab
)
× 100%.
Titer values recorded below the LLOD were assigned a titer of
<10 for the sample, and a titer of 5 for the GMT  analysis. To obtain
the equivalent result in concentration, the titer value was mul-
tiplied by 2 g/mL, a coefﬁcient derived from several reference
curves from multiple experiments (data not shown).
2.5. Microneutralization assay
To determine whether passively transferred anti-RSV F anti-
bodies and palivizumab can elicit RSV F neutralizing antibodies,
sera samples from sows (PND0) and pups (PND0, PND15, PND30)
were assayed in a RSV/A (Long strain) neutralization assay as
previously described [11]. Two-fold serial dilutions of guinea pig
sera, starting at 1:10, were prepared in 96-well plates. The neu-
tralizing antibody titer was identiﬁed as the last dilution that
resulted in 60% inhibition of cytopathic effect (CPE) observed in
virus-only infected wells. Sera that showed no inhibition in CPE
6490 G.M. Glenn et al. / Vaccine 33 (2015) 6488–6492
Table 2
Summary of pregnancy rates, birth outcomes, and pup serology cohorts.
Guinea pigs Number of pups
Treatment groups Presumed
pregnant (N)
Pregnant Sows with ≥1
stillborn pup
Live
pups (N)
Total
stillborn (N)
PND0
serology (N)
PND15/30
serology (N)
1-Placebo 10 8 (80%) 3a 33 9 17 16
2-RSV F 10 8 (80%) 0 29 0 14 15/14b
3-RSV F + AlPO4 10 9 (90%) 3 32 3 15 17
PND = Post Natal Day; AlPO4 = aluminum phosphate.
a One sow in the placebo group delivered 7 stillborn pups.
d 30 blood collection to 14.
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Fig. 1. Maternal antibody transfer. Three groups of pregnant guinea pigs received
two intramuscular (IM) doses on Gestation Days (GD) 25 and 46 with placebo (PBS),
30  g RSV F (unadjuvanted), or 30 g RSV F + 400 g AlPO4. Serum was obtained
from sows (white bars) and pups (black bars) on Post Natal Day 0 (PND0, deliv-b One pup died on PND5 reducing the number of pups assigned for the PND 15 an
t the 1:20 dilution were assigned a value of 10 for the GMT
nalysis.
.6. Statistical analysis
The GMT  (anti-RSV F IgG and RSV/A MN)  or GMC  (PCA) and
ssociated 95% conﬁdence interval (CI) were calculated for each
reatment group.
. Results
.1. Rate of pregnancy and pup survivability
In this study, three treatment groups of presumed pregnant
uinea pigs received immunization with active vaccine or placebo
n their third trimester on GD25 and 46. Pregnant females carried to
erm and delivered pups between 61 and 71 days of gestation. The
verall rate of pregnancy achieved in this study was  83.3% (25/30
resumed pregnant guinea pigs delivered between GD61-71) with
itter size range 1 to 8 (Table 2). In Group 1 (placebo), 8/10 females
elivered 33 live and 9 stillborn pups, which resulted in an 80%
elivery rate. Similarly, 8/10 guinea pigs in Group 2 (RSV F alone)
elivered 29 live (and 0 stillborn) pups, resulting in an 80% delivery
ate. In Group 3 (RSV F + AlP04), 9/10 females delivered 32 live and
 stillborn pups indicating a delivery rate of 90%. One female from
roup 1 delivered 7 stillborn from a litter of 8 pups due to the large
itter size (8) compared to an average of 3 seen with most females
or this species [12,13]. The two remaining stillbirths in the placebo
roup and the 3 stillbirths in the adjuvanted RSV F group, involved
nly 1 pup per female; indicating the stillbirths were not related to
accine administration as it occurred with similar frequency in the
lacebo and the adjuvanted RSV F vaccine groups.
.2. Evaluation of immune responses in guinea pig sows
Anti-RSV F IgG responses, PCA, and RSV/A MN  were measured
n serum samples obtained from individual sows on the day of
elivery, designated as Post Natal Day 0 (PND0). The titers for
aternal samples in the placebo group were below the detec-
ion or minimum dilution level for the anti-RSV F IgG, PCA, and
SV/A MN  assays (Fig. 1). Pregnant guinea pigs immunized with
nadjuvanted and AlPO4-adjuvanted RSV F resulted in high anti-
SV F IgG titers (GMT = 20,620 and 374,506, respectively), with
8.2-fold higher RSV F IgG titers in adjuvanted vaccine recipients
Fig. 1A). Similarly, PCA concentrations obtained with unadju-
anted and AlPO4-adjuvanted RSV F were also robust (GMT = 139
nd 1,553 g/mL, respectively) and levels were 11.2-fold higher
ith the adjuvanted vaccine (Fig. 1B). RSV/A MN  levels in unadju-
anted RSV F vaccine recipients reached a GMT  of 73, but were
.8-fold higher (GMT of 718) in adjuvanted vaccine recipients
Fig. 1C).
ery/birth) for determination of (A) anti-RSV F IgG, (B) palivizumab-competitive
antibody (PCA), and (C) RSV/A neutralizing antibody levels as described in the
Materials and Methods section. Data shown are the GMT/GMC and 95% CI for each
immunological assay by treatment group.
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Fig. 2. Antibody levels in pups of immunized sows. Pups born to pregnant guinea
pigs  immunized with placebo (PBS), 30 g RSV F, or 30 g RSV F + 400 g AlPO4 on
GD25 and 46 had sera collected on PND0 (white bars), PND15 (hatched bars) and
PND30 (black bars) for evaluation of (A) anti-RSV F IgG, (B) PCA, and (C) RSV/A MN
antibody titers/concentration as described in the Materials and Methods section.
Data  shown are the GMT/GMC and 95% CI for each immunological assay by treatmentG.M. Glenn et al. / Vac
.3. Evaluation of RSV F vaccine induced maternal antibodies in
ups
Pups assigned to PND0 were terminally bled to determine their
nti-RSV F IgG titers, PCA concentrations, and RSV/A MN titers.
he GMTs for pups born to sows that received placebo were very
ow or below the detection level for all three assays. All the pups
orn to RSV F (both adjuvanted and unadjuvanted) vaccinated
ows generated anti-RSV F speciﬁc immune responses indicating
fﬁcient maternal antibody transfer during the gestation period
Fig. 1).
Pups born to unadjuvanted RSV F vaccinated sows had anti-RSV
 IgG GMT  of 63,036; PCA concentration of 292 g/mL; and RSV/A
N GMT  of 160 (Fig. 1). Importantly, antibody levels were higher
ompared to those measured in matched maternal sera (20,620;
39 g/mL; and 73, for anti-RSV F IgG, PCA, and RSV/A MN,  respec-
ively), indicating a relative concentration of antibody in pups by
06, 210, and 219%, respectively.
Similarly, pups born to adjuvanted RSV F vaccinated sows had
nti-RSV F IgG, PCA, and RSV/A neutralizing GMTs of 832,277;
,427 g/mL; and 1,194, respectively (Fig. 1). As seen for the RSV F
reatment group, antibody levels were higher in the pups compared
o matched sows (374,506; 1,553 g/mL; and 718, respectively),
ndicating a relative concentration of antibody in pup sera by 222,
56, and 166%, respectively (Fig. 2).
All remaining pups not assigned to PND0 were housed with
heir mother until weaning on PND15. Relative to PND0 antibody
evels, anti-RSV F IgG, PCA, and RSV/A MN GMTs/concentrations
eclined on PND15 in all pups of both RSV F vaccine recipients
GMT/concentration of 14,863; 68 g/mL; and 44, respectively)
nd adjuvanted RSV F vaccine recipients (159,263; 521 g/mL;
nd 333, respectively). Although further decreases in antibodies
ere noted at PND30; detectable levels remained, demonstrating
he persistence of maternally-transferred RSV F-speciﬁc antibodies
n pups. Given that pups continued to breastfeed through PND15
nd intestinal Fc receptor-mediated antibody uptake is a signiﬁ-
ant mechanism to attain high-level serum titers post-partum, the
alf-life of RSV F antibodies was not calculated.
. Discussion
Maternal immunization has been most successfully imple-
ented by a WHO  global immunization campaign to address
eonatal tetanus. Since the program’s inception, the incidence
f neonatal tetanus has been signiﬁcantly reduced [1]. Similarly,
nﬂuenza immunization of pregnant women has demonstrated efﬁ-
acy against inﬂuenza disease in both the woman and her infant,
n the absence of any adverse impacts on either the course of the
regnancy or the neonate [3,10,14,15]. Finally, the implementation
f third-trimester maternal immunization with pertussis has had
ramatic effects on the incidence of pertussis where the uptake of
he vaccine has been high [2].
In humans, maternal IgG antibodies are transplacentally-
ransferred to the fetus by active transcytosis facilitated by IgG Fc
eceptors expressed on the placenta [16]. The active transport of IgG
ntibodies generally results in enhanced antibody concentrations
n cord blood, often in excess of maternal levels [17] and favors IgG1
18]. Accordingly, it is a reasonable expectation that raising func-
ional anti-RSV F antibody levels in pregnant woman  will increase
iters of functional anti-RSV F antibodies in infants [18,19]; thus we
ndeavored to model this in guinea pigs.In this GLP study, pregnant guinea pigs were immunized with
he clinical stage RSV F nanoparticle vaccine, and vaccine effects
n rates of pregnancy and rates of live births were observed in a
ontrolled setting. When assessed in the context of the publishedgroup.
literature [12], no untoward effects were observed as all pregnant
guinea pigs vaccinated with unadjuvanted or adjuvanted RSV F on
GD25 and 46 carried to full-term. The overall pregnancy rate was
83.3% for all three treatment groups, with a litter size range of 1
to 8 pups, for a total of 94 live births and 12 stillbirths. Among
the stillborn pups, 9 were in the placebo group (21.4%) and 3 were
in the adjuvanted RSV F group (8.6%). Among the 9 stillbirths in
the placebo group, 7 were from one guinea pig with a litter of 8
pups indicating the stillbirth was associated with the unusually
large litter size compared to the average of 3 pups for this species
[12,13]. All of the other stillbirths that occurred in the placebo and
the adjuvanted RSV F groups involved only one pup per female.
Overall, the delivery rates and the number of pups born between
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he placebo group and the active vaccine groups were similar, indi-
ating RSV F vaccination of pregnant guinea pigs did not result in
dverse effects on gestation. In general, these outcomes are in line
ith historical rates of pregnancy and stillbirth in lab-raised guinea
igs [12,13].
Robust anti-RSV F IgG, PCA concentrations, and RSV/A neutral-
zing titers were detected in sera from RSV F vaccinated sows,
onsistent with previous observations in cotton rats [20], mice [21],
nd humans [11]. Similar to previous studies in all species, AlPO4-
djuvanted RSV F vaccine administered to pregnant guinea pigs
licited a higher RSV F-speciﬁc antibody response than the unad-
uvanted RSV F vaccine. Pups born to RSV F vaccinated sows had
igh levels of anti-RSV F IgG, PCA, and RSV/A neutralizing antibod-
es at birth, and concentration effects, relative to levels in matched
aternal sera, was observed with all serological measures. The
bserved transplacental concentration of antibodies is similar, or
ossibly more robust to that generally observed in humans [19],
ith the exception of the MN  antibody response. Several studies in
umans measuring MN  antibodies derived from natural infection,
ave described a relative parity of infant and maternal MN levels
22,23]. This may  be explained by the high variability of neutraliz-
ng antibodies elicited by natural infection in humans [24], whereas
he vaccine, given at a consistent dose in naïve guinea pigs, may
nduce a relatively constant MN  titer (see 95% CI for example) that
llows a more precise measure of placental transfer. Alternatively,
he RSV F vaccine may  elicit antibody responses of higher quality,
haracterized by increased binding afﬁnity to the F protein, which
ay  be more efﬁciently transferred. It is also possible the guinea
ig model may  not be a suitable paradigm to model human placen-
al antibody transfer as measured by MN.  The current trial of the
SV F nanoparticle vaccine in third-trimester pregnant women  and
heir infants (Clin. trials.gov, NCT02247726) is designed to measure
he placental transfer of these antibodies, and will either conﬁrm
r reject these hypotheses.
As noted, pups born to RSV F-immunized sows had robust
nti-RSV F IgG, PCA, and neutralizing antibody levels in their
erum. Levels declined after birth, but persisted through 30 days
ost-partum, and were notably highest in pups born to sows
accinated with AlLPO4-adjuvanted RSV F. The relatively short
alf-life, consistent with the literature on guinea pigs [25], does
ot reﬂect the general experience with transplacentally-derived
uman IgG directed to RSV [22,26]. There are several factors,
ncluding the comparatively more rapid increase in relative body
eight (compared to human infants) and subsequent increase
n volume of distribution for serum antibodies that may  explain
his ﬁnding. Speciﬁc conﬁrmation of the decay kinetics of these
ransplacentally-derived antibodies in humans may  shed fur-
her light in determining whether the guinea pig is a suitable
odel to predict the half-life of RSV F-speciﬁc antibodies in
umans.
In summary, this study provides further evidence that the RSV
 vaccine may  be safely administered during pregnancy—a ﬁnding
n line with the ﬁrst in human study with a virus-derived puriﬁed
 protein in pregnant women [27]. It also demonstrates the trans-
er of placental anti-RSV F antibodies, as measured using different
mmunoassays, and concentration of these antibodies in pups in
omparison to their respective birth mothers. Although further
valuation of the safety of the vaccine in pregnant women and
heir infants should be approached with caution, the disease bur-
en in humans and the preclinical safety, immunogenicity, efﬁcacy,
nd transplacental transfer data collectively underscore that devel-
pment of the RSV F vaccine to protect mothers and their infants
gainst RSV disease should continue.
[
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